New clinical practice data for Bial's Zebinix

Portugal’s Bial and Japan-based licensee Eisai (TYO: 4523) have announced new clinical practice data from the Euro-Esli study of Zebinix (eslicarbazepine acetate).

The trial demonstrates safety and clinical effectiveness as an adjunctive therapy in people with focal epilepsy and with psychiatric co-morbidities, including intellectual disability, compared with people with no psychiatric co-morbidities.

At 12 months, the responder rate was  83.1% and the seizure freedom rate was 51.3%, compared with 82.5% and 51.4% respectively, for people without psychiatric comorbidities.